# IAMRT 2025 ì¢…í•© í•™íšŒ ê³„íš
## International Workshop on Antimicrobial Resistance & Antibiotic Development

**ì°¸ì„ì í”„ë¡œí•„**: í¬ë‹¥ ì—°êµ¬ì, ì—°êµ¬ ê´€ì‹¬ì‚¬: ëª¨ë“  ì£¼ì œ (ë°”ì´ì˜¤ì¸í¬ ì¤‘ì‹¬), ëª©í‘œ: ì—°êµ¬ë™í–¥íŒŒì•…

**ì‘ì„±ì¼**: 2025ë…„ 10ì›” 29ì¼
**í•™íšŒ ì¼ì‹œ**: 2025ë…„ 10ì›” 30ì¼ (ëª©ìš”ì¼) 12:00-18:30
**ì¥ì†Œ**: ì„±ê· ê´€ëŒ€í•™êµ ì˜ê³¼ëŒ€í•™, AI ê°•ì˜ì‹¤ 3304

---

## ğŸ¯ Executive Summary

### Top 5 Must-Attend Sessions

1. **Session 1: Antimicrobial Resistance** (12:10-13:25) - â­â­â­â­â­
   - Patriq Fagerstedt: EU OHAMR Partnership (êµ­ì œ í˜‘ë ¥ ì „ëµ)
   - Hongbaek Cho: Secretin plugs (êµ¬ì¡° ìƒë¬¼í•™ + AMR)
   - Jinki Yeom: ASM antibiotics (ì‹ ê·œ í™”í•™ scaffold)

2. **Session 3: Host-Pathogen Interaction** (15:10-16:25) - â­â­â­â­â­
   - Eun-Kyeong Jo: Autophagy (Host-directed therapy)
   - Jung-Hyun Kim: Organoid + macrophage (ì²¨ë‹¨ ëª¨ë¸)
   - Hyunjung Lee: AI + HTS (ë°”ì´ì˜¤ì¸í¬ ì§ì ‘ ì—°ê´€!)

3. **Session 4: Antibiotic Development** (16:40-17:55) - â­â­â­â­â­
   - Jaehoon Yu: Drug repurposing + CPP
   - Hee-Jong Hwang: Thiopeptides (ìì—°ë¬¼ â†’ ì‹ ì•½)
   - Yan Lee: pH-responsive peptides (rational design)

4. **Session 2: Bacterial Pathogenesis** (13:40-14:55) - â­â­â­â­â˜†
   - Sung Jae Shin: MTB vs. MAC ì°¨ì´ (í•œêµ­ ì—­í•™)
   - You-Hee Cho: ROS pharmacophores
   - Wonsik Lee: S. aureus Tn-seq (ìœ ì „ì²´í•™!)

5. **Panel Discussion** (17:55-18:30) - â­â­â­â­â˜…
   - "How to End AMR?" - ëª¨ë“  ì—°ì‚¬ ì°¸ì—¬
   - ë„¤íŠ¸ì›Œí‚¹ ê³¨ë“  íƒ€ì„

### ì™œ ì´ í•™íšŒê°€ ì¤‘ìš”í•œê°€?

**1. ë°”ì´ì˜¤ì¸í¬ ê´€ì ì—ì„œ ìµœì **
- Session 2: Tn-seq (Wonsik Lee) - ìœ ì „ì²´ ë¶„ì„ì˜ ì •ìˆ˜
- Session 3: scRNA-seq (Jung-Hyun Kim), ML (Hyunjung Lee) - AI í†µí•©
- Session 4: Structure-based design (ëª¨ë“  ë°œí‘œ) - êµ¬ì¡° ìƒë¬¼ì •ë³´

**2. ì—°êµ¬ ë™í–¥ì„ í•œëˆˆì—**
- AMR êµ­ì œ í˜‘ë ¥ (EU OHAMR)
- Host-directed therapy ìµœì‹  ë™í–¥
- ì‹ ì•½ ê°œë°œ íŒŒì´í”„ë¼ì¸ (ë°”ì´ì˜¤í… CEO ì§ì ‘ ë°œí‘œ)

**3. ë„¤íŠ¸ì›Œí‚¹ ê¸°íšŒ**
- êµ­ë‚´ ìµœê³  ì—°êµ¬ì (Yonsei, SKKU, SNU, CHA)
- ë°”ì´ì˜¤í… CEO 2ëª… (CAMP, A&J)
- Institut Pasteur Korea (í˜‘ë ¥ ê¸°íšŒ)
- êµ­ì œ ì—°ì‚¬ (Patriq Fagerstedt, ìŠ¤ì›¨ë´)

**4. í¬ë‹¥ ê²½ë ¥ ê°œë°œ**
- ìµœì‹  ê¸°ìˆ  (Organoid, Tn-seq, AI/ML)
- ì‚°í•™ ì—°ê³„ ëª¨ë¸
- ë°”ì´ì˜¤í… ì°½ì—… ì‚¬ë¡€

---

## ğŸ“… Day-by-Day Schedule

### 2025ë…„ 10ì›” 30ì¼ (ëª©ìš”ì¼) - ë‹¨ì¼ì¼ ì›Œí¬ìˆ

#### 12:00-12:10 | Opening Remarks
**ì—°ì‚¬**: Kyeong Kyu Kim (Sungkyunkwan University)

**ì¤€ë¹„ì‚¬í•­**:
- [ ] 11:50 ë„ì°© (ì—¬ìœ  ìˆê²Œ)
- [ ] ì•ìë¦¬ í™•ë³´ (ì§ˆë¬¸ ì‹œ ëˆˆì— ë„ê²Œ)
- [ ] ëª…í•¨ 30ì¥, ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ ì¤€ë¹„
- [ ] ì˜¤í”„ë‹ ì¤‘ ì—°ì‚¬ì§„ ê´€ì°° (ëˆ„ê°€ ì™”ëŠ”ì§€)

**ì˜ˆìƒ ë‚´ìš©**:
- AMR ìœ„ê¸° ê°œìš”
- IAMRT ì†Œê°œ (Institute for Antimicrobial Resistance Research and Therapeutics)
- ì„±ê· ê´€ëŒ€ ì—­í• 
- ì›Œí¬ìˆ ëª©í‘œ

**Action**:
- AMR statistics ë©”ëª¨ (í•œêµ­ vs. ê¸€ë¡œë²Œ)
- IAMRT ì—°êµ¬ ë¶„ì•¼ íŒŒì•…

---

#### 12:10-13:25 | Session 1: Antimicrobial Resistance

##### 12:10-12:35 | OH AMR: How to fight against AMR
**ì—°ì‚¬**: Patriq Fagerstedt (Swedish Research Council)

**í•µì‹¬ í¬ì¸íŠ¸**:
- EU One Health AMR Partnership (â‚¬340M+)
- 53ê°œ ê¸°ê´€, 30ê°œêµ­ í˜‘ë ¥
- í•œêµ­ ì°¸ì—¬: IAMRT (ì„±ê· ê´€ëŒ€)
- One Health approach (ì¸ê°„-ë™ë¬¼-í™˜ê²½ í†µí•©)

**Why ì¤‘ìš”**:
- êµ­ì œ í˜‘ë ¥ ëª¨ë¸ ì´í•´
- EU grant ê¸°íšŒ íŒŒì•…
- One Health ë°ì´í„° í†µí•© (ë°”ì´ì˜¤ì¸í¬ ì—°ê´€)

**ì§ˆë¬¸ í›„ë³´**:
- "í•œêµ­ ì—°êµ¬ìê°€ EU OHAMRì— ì°¸ì—¬í•˜ë ¤ë©´ ì–´ë–¤ ê²½ë¡œê°€ ìˆë‚˜ìš”?"
- "OHAMRì—ì„œ ë°”ì´ì˜¤ì¸í¬/ë°ì´í„° ì‚¬ì´ì–¸ìŠ¤ ì—­í• ì€?"

**ë„¤íŠ¸ì›Œí‚¹**:
- ë°œí‘œ í›„ ì ‘ê·¼ (êµ­ì œ í˜‘ë ¥ ë…¼ì˜)
- ëª…í•¨ êµí™˜ í•„ìˆ˜

---

##### 12:35-13:00 | Secretin-interacting plug proteins prevent antibiotic influx
**ì—°ì‚¬**: Hongbaek Cho (Sungkyunkwan University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- SlkA, SlkB (PA5122, PA5123) - Secretin channel "í”ŒëŸ¬ê·¸"
- Pseudomonas aeruginosa ì™¸ë§‰ íˆ¬ê³¼ ì°¨ë‹¨
- Type IV pilus ì¡°ë¦½ ë©”ì»¤ë‹ˆì¦˜
- êµ¬ì¡° ìƒë¬¼í•™ (cryo-EM, AlphaFold2)

**Why ì¤‘ìš”**:
- êµ¬ì¡° ê¸°ë°˜ ì•½ë¬¼ ì„¤ê³„ (ë°”ì´ì˜¤ì¸í¬ í™œìš©)
- AlphaFold2 ì‘ìš© ì‚¬ë¡€
- ì™¸ë§‰ biology ìµœì‹  ì´í•´

**ì§ˆë¬¸ í›„ë³´**:
- "SlkA/SlkB êµ¬ì¡° ì˜ˆì¸¡ ì‹œ AlphaFold2 vs. cryo-EM ê²°ê³¼ ì°¨ì´ëŠ”?"
- "Secretin plugë¥¼ íƒ€ê²ŸíŒ…í•˜ëŠ” ì•½ë¬¼ ì„¤ê³„ ê°€ëŠ¥ì„±ì€?"

**ë„¤íŠ¸ì›Œí‚¹**:
- SKKU ë™ë¬¸/ì¬í•™ìƒì´ë©´ ì ê·¹ ì ‘ê·¼
- Lab visit ìš”ì²­ (ìˆ˜ì› ìº í¼ìŠ¤)

---

##### 13:00-13:25 | A new class of antibiotics targets outer layer glycolipid biosynthesis
**ì—°ì‚¬**: Jinki Yeom (Seoul National University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- ASM (Amino acid-based Small Molecules)
- LPS/LTA ìƒì„± íš¨ì†Œ ì–µì œ
- CRAB (carbapenem-resistant A. baumannii), MRSA íš¨ê³¼
- PGM (phosphoglucosamine mutase) í‘œì 

**Why ì¤‘ìš”**:
- ì‹ ê·œ í™”í•™ scaffold
- ê·¸ëŒì–‘ì„± + ê·¸ëŒìŒì„± ëª¨ë‘ íš¨ê³¼ (ë“œë¬¾)
- êµ¬ì¡° ìµœì í™” ê³¼ì • (med chem)

**ì§ˆë¬¸ í›„ë³´**:
- "ASMì˜ SAR (structure-activity relationship) ì—°êµ¬ ê²°ê³¼ëŠ”?"
- "PGM ì–µì œì œê°€ ì •ìƒ ê· ì´ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€?"

**ë„¤íŠ¸ì›Œí‚¹**:
- SNU ì¶œì‹ ì´ë©´ ì ê·¹ ì ‘ê·¼
- Biomedical Science í•™ê³¼ (ê´€ì•…)

---

**13:25-13:40 | Break (15ë¶„)**

**í™œìš© ì „ëµ**:
- ì»¤í”¼/ê°„ì‹ (ê°„ë‹¨íˆ)
- ë©”ëª¨ ì •ë¦¬ (Session 1 í•µì‹¬)
- ëª…í•¨ í™•ì¸ (ë°›ì€ ê²ƒ)
- Session 2 ì¤€ë¹„ (ì§ˆë¬¸ ì¬í™•ì¸)

---

#### 13:40-14:55 | Session 2: Bacterial Pathogenesis

##### 13:40-14:05 | Two major mycobacterial pathogens in South Korea
**ì—°ì‚¬**: Sung Jae Shin (Yonsei University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- MTB vs. MAC ë³‘ì›ì„± ì°¨ì´
- Type I IFN pathway (Mtb), ì§€ë°©ì‚° ëŒ€ì‚¬ (MAC)
- Host-directed therapy (JAK inhibitor, STING agonist)
- C3H/HeJ vs. A/J ë§ˆìš°ìŠ¤ ëª¨ë¸

**Why ì¤‘ìš”**:
- í•œêµ­ íŠ¹ì´ì  ì—­í•™ (NTM ê¸‰ì¦)
- HDT ì„ìƒ ê°€ëŠ¥ì„±
- ë©´ì—­ëŒ€ì‚¬ ì—°êµ¬ (systems biology ì—°ê´€)

**ì§ˆë¬¸ í›„ë³´**:
- "MAC í™˜ìì˜ ì§€ë°©ì‚° profileì„ ë°”ì´ì˜¤ë§ˆì»¤ë¡œ ì“¸ ìˆ˜ ìˆë‚˜ìš”?"
- "Type I IFN ì°¨ë‹¨ ì‹œì ì„ ì˜ˆì¸¡í•˜ëŠ” ëª¨ë¸ì´ ìˆë‚˜ìš”?"

**ë„¤íŠ¸ì›Œí‚¹**:
- Yonsei ì¸ê·¼ (ì‹ ì´Œ)
- Lab visit ìš©ì´

---

##### 14:05-14:30 | Antibacterial strategies based on ROS pharmacophores
**ì—°ì‚¬**: You-Hee Cho (CHA University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- Organoruthenium complex (ROS ìƒì„±)
- Pharmacophore-based design
- Designer phage (Cas9 + ROS)
- P. aeruginosa, MRSA biofilm ì œê±°

**Why ì¤‘ìš”**:
- í™”í•™ + ë¯¸ìƒë¬¼í•™ ìœµí•©
- Phage therapy ìµœì‹  ë™í–¥
- Metal-based drugs

**ì§ˆë¬¸ í›„ë³´**:
- "Designer phageì˜ Cas9 target ì„ íƒ ê¸°ì¤€ì€?"
- "ROS pharmacophore ì„¤ê³„ ì‹œ computational screening ì‚¬ìš©í•˜ë‚˜ìš”?"

**ë„¤íŠ¸ì›Œí‚¹**:
- CHA University (ê²½ê¸° í¬ì²œ)
- Phage therapy ê´€ì‹¬ ì‹œ ì ê·¹ ì ‘ê·¼

---

##### 14:30-14:55 | Discovery and functional characterization of novel antibiotic targets in S. aureus
**ì—°ì‚¬**: Wonsik Lee (Sungkyunkwan University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- Transposon sequencing (Tn-seq)
- í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì (í˜ˆë¥˜, ì„¸í¬ ë‚´, ì¡°ì§)
- DHQD, Sortase A, Serine hydrolases (ì‹ ê·œ í‘œì )
- Tn-seq â†’ target validation â†’ drug discovery

**Why ì¤‘ìš” (ë°”ì´ì˜¤ì¸í¬ ìµœê³ !)**:
- Tn-seq ë°ì´í„° ë¶„ì„ (DESeq2, EdgeR)
- Genomics â†’ ì•½ë¬¼ í‘œì  ë°œêµ´ íŒŒì´í”„ë¼ì¸
- Nature Communications 2025 (ìµœì‹ )

**ì§ˆë¬¸ í›„ë³´ (ë°”ì´ì˜¤ì¸í¬ ê´€ì )**:
- "Tn-seq ë°ì´í„° ë¶„ì„ ì‹œ false positive ì œê±° ì „ëµì€?"
- "í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì predictionì„ MLë¡œ í•  ìˆ˜ ìˆë‚˜ìš”?"
- "Tn-seq ì½”ë“œ/íŒŒì´í”„ë¼ì¸ ê³µìœ  ê°€ëŠ¥í•œê°€ìš”?"

**ë„¤íŠ¸ì›Œí‚¹ (ìµœìš°ì„ !)**:
- **ë°”ì´ì˜¤ì¸í¬ ì§ì ‘ ì—°ê´€**
- Lab visit í•„ìˆ˜ (SKKU ì•½í•™ëŒ€í•™, ìˆ˜ì›)
- Collaboration ê°€ëŠ¥ì„± ë†’ìŒ (RNA-seq + Tn-seq í†µí•©)

---

**14:55-15:10 | Break (15ë¶„)**

**í™œìš© ì „ëµ**:
- Wonsik Leeì—ê²Œ ì¦‰ì‹œ ì ‘ê·¼ (ë°”ì´ì˜¤ì¸í¬ í˜‘ë ¥)
- ëª…í•¨ êµí™˜ + Tn-seq ë…¼ì˜
- Lab visit ì¼ì • ì œì•ˆ

---

#### 15:10-16:25 | Session 3: Host-Pathogen Interaction

##### 15:10-15:35 | Autophagy in Mycobacterial Infection
**ì—°ì‚¬**: Eun-Kyeong Jo (Chungnam National University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- ATG7 knockout â†’ NTM ê°ì—¼ ì•…í™” (Nature Commun 2025)
- Autophagy = Host-directed therapy í•µì‹¬
- mTOR, AMPK ì¡°ì ˆ (rapamycin, metformin)
- Inflammasome crosstalk

**Why ì¤‘ìš”**:
- HDT ë©”ì»¤ë‹ˆì¦˜ ì´í•´
- ì„ìƒ ì ìš© ê°€ëŠ¥ì„± (metformin repurposing)
- Systems biology (autophagy network)

**ì§ˆë¬¸ í›„ë³´**:
- "Autophagy pathwayë¥¼ systems biologyë¡œ ëª¨ë¸ë§í•œ ì—°êµ¬ëŠ”?"
- "Metformin ì„ìƒì‹œí—˜ ê³„íšì´ ìˆë‚˜ìš”?"

**ë„¤íŠ¸ì›Œí‚¹**:
- ì¶©ë‚¨ëŒ€ (ëŒ€ì „)
- Autophagy ê´€ì‹¬ ì‹œ

---

##### 15:35-16:00 | Pluripotent stem cell derived macrophages and lung organoids
**ì—°ì‚¬**: Jung-Hyun Kim (Ajou University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- hPSC â†’ Macrophage + Alveolar organoid
- scRNA-seq ë¶„ì„ (ê°ì—¼ ì‹œ)
- SARS-CoV-2, Mtb ëª¨ë¸ë§
- Patient-derived organoid (ë§ì¶¤ ì˜í•™)

**Why ì¤‘ìš” (ë°”ì´ì˜¤ì¸í¬!)**:
- **scRNA-seq ë°ì´í„° ë¶„ì„**
- Organoid + immune cells ëª¨ë¸
- Spatial transcriptomics ê°€ëŠ¥ì„±

**ì§ˆë¬¸ í›„ë³´ (ë°”ì´ì˜¤ì¸í¬)**:
- "Organoid scRNA-seq ë¶„ì„ ì‹œ batch effect ì œê±° ì „ëµì€?"
- "Cell-cell interaction ë¶„ì„ íˆ´ì€? (CellPhoneDB, NicheNet?)"
- "Public data ê³µìœ  ê³„íšì€?"

**ë„¤íŠ¸ì›Œí‚¹ (ìš°ì„ ìˆœìœ„ ë†’ìŒ!)**:
- **scRNA-seq í˜‘ë ¥ ê°€ëŠ¥**
- Ajou University (ìˆ˜ì›)
- Organoid + computational biology

---

##### 16:00-16:25 | Development and optimization of infection model for antimicrobial discovery
**ì—°ì‚¬**: Hyunjung Lee (Institut Pasteur Korea)

**í•µì‹¬ í¬ì¸íŠ¸**:
- H460 + GFP-S. aureus ê°ì—¼ ëª¨ë¸
- High-content imaging + Machine Learning
- Hit rate 14ë°° í–¥ìƒ (ML ì‚¬ìš©)
- 2,320 compound screening

**Why ì¤‘ìš” (ë°”ì´ì˜¤ì¸í¬ ìµœê³ !)**:
- **ML in drug discovery**
- High-content imaging ë¶„ì„
- Feature engineering, classification

**ì§ˆë¬¸ í›„ë³´ (ë°”ì´ì˜¤ì¸í¬/ML)**:
- "ML ëª¨ë¸ architectureëŠ”? (Random Forest? CNN?)"
- "Feature selection ë°©ë²•ì€? (PCA? LASSO?)"
- "Training data augmentation ì „ëµì€?"
- "Code/pipeline ê³µìœ  ê°€ëŠ¥í•œê°€ìš”?"

**ë„¤íŠ¸ì›Œí‚¹ (ìµœìš°ì„ !)**:
- **Institut Pasteur Korea (íŒêµ) - ì ‘ê·¼ ì‰¬ì›€**
- **ML/AI collaboration ì§ì ‘ ê°€ëŠ¥**
- HTS facility ì´ìš© ê°€ëŠ¥ì„±
- Internship/Postdoc ê¸°íšŒ

---

**16:25-16:40 | Break (15ë¶„)**

**í™œìš© ì „ëµ**:
- Jung-Hyun Kim, Hyunjung Lee ì ‘ê·¼ (ë°”ì´ì˜¤ì¸í¬ í˜‘ë ¥)
- scRNA-seq, ML êµ¬ì²´ì  ë…¼ì˜
- ëª…í•¨ êµí™˜ + í›„ì† ë¯¸íŒ… ì œì•ˆ

---

#### 16:40-17:55 | Session 4: Antibiotic Development

##### 16:40-17:05 | Repositioning methotrexate by conjugating to Gram-negative specific penetrating peptide
**ì—°ì‚¬**: Jaehoon Yu (CAMP Therapeutics)

**í•µì‹¬ í¬ì¸íŠ¸**:
- MTX-CPP conjugate
- E. coli NDM1 íš¨ê³¼ (carbapenem ë‚´ì„±)
- Drug repurposing ì „ëµ
- Preclinical development

**Why ì¤‘ìš”**:
- ë°”ì´ì˜¤í… ì°½ì—… ì‚¬ë¡€
- FDA pathway ê²½í—˜
- Drug design (computational docking?)

**ì§ˆë¬¸ í›„ë³´**:
- "CPP-antibiotic conjugate ì„¤ê³„ ì‹œ computational screening í–ˆë‚˜ìš”?"
- "CAMPì—ì„œ ë°”ì´ì˜¤ì¸í¬ í¬ë‹¥ ì±„ìš© ê³„íšì€?"

**ë„¤íŠ¸ì›Œí‚¹**:
- ë°”ì´ì˜¤í… ì§„ë¡œ ê´€ì‹¬ ì‹œ ì ê·¹
- CEOì™€ ì§ì ‘ ëŒ€í™” ê¸°íšŒ

---

##### 17:05-17:30 | Developing New Antibiotics from Thiopeptide Natural Products
**ì—°ì‚¬**: Hee-Jong Hwang (A&J Science)

**í•µì‹¬ í¬ì¸íŠ¸**:
- Micrococcin P2 derivatives
- C. difficile, NTM íš¨ê³¼
- GMP ìƒì‚° (decagram scale)
- Orphan drug designation

**Why ì¤‘ìš”**:
- ìì—°ë¬¼ â†’ ì‹ ì•½ íŒŒì´í”„ë¼ì¸
- Structure optimization (SAR)
- Regulatory strategy

**ì§ˆë¬¸ í›„ë³´**:
- "Thiopeptide SAR ì—°êµ¬ ì‹œ computational chemistry ì‚¬ìš©í–ˆë‚˜ìš”?"
- "Microbiome ë¶„ì„ (16S sequencing) ë°ì´í„°ëŠ”?"

**ë„¤íŠ¸ì›Œí‚¹**:
- ìì—°ë¬¼ + ë°”ì´ì˜¤ì¸í¬ ìœµí•©
- A&J Science (ë°”ì´ì˜¤í…)

---

##### 17:30-17:55 | Hinged amphipathic peptides with pH-inducible positive charges
**ì—°ì‚¬**: Yan Lee (Seoul National University)

**í•µì‹¬ í¬ì¸íŠ¸**:
- KLH3/KLH4 (pH-responsive)
- Histidine-rich peptides
- A. baumannii, E. coli íš¨ê³¼
- Rational design

**Why ì¤‘ìš”**:
- Peptide design (computational modeling)
- Structure-based optimization
- Precision medicine ê°œë…

**ì§ˆë¬¸ í›„ë³´**:
- "Peptide structure prediction (AlphaFold2, RoseTTAFold)ì‚¬ìš©í–ˆë‚˜ìš”?"
- "pH-responsive mechanismì„ MD simulationìœ¼ë¡œ ê²€ì¦í–ˆë‚˜ìš”?"

**ë„¤íŠ¸ì›Œí‚¹**:
- SNU Chemistry (ê´€ì•…)
- Computational chemistry í˜‘ë ¥

---

#### 17:55-18:30 | Panel Discussion: How to End AMR?

**íŒ¨ë„**: ì „ì²´ ì—°ì‚¬ (13ëª…)

**ì˜ˆìƒ ì£¼ì œ**:
- AMR ìœ„ê¸° ê·¹ë³µ ì „ëµ
- êµ­ì œ í˜‘ë ¥ í•„ìš”ì„±
- ì‹ ì•½ ê°œë°œ ë³‘ëª©
- ì •ë¶€ ì •ì±… ì œì•ˆ
- í•™ê³„-ì‚°ì—… ì—°ê³„

**ì°¸ì—¬ ì „ëµ**:
- ì²­ì¤‘ ì§ˆë¬¸ ê¸°íšŒ (ì† ë“¤ê¸°)
- íŒ¨ë„ ê°„ í† ë¡  ê´€ì°°
- ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ ìµœì¢… í™•ì •

**ì§ˆë¬¸ í›„ë³´ (íŒ¨ë„ì—ê²Œ)**:
- "ë°”ì´ì˜¤ì¸í¬/AIê°€ AMR ê·¹ë³µì— ì–´ë–»ê²Œ ê¸°ì—¬í•  ìˆ˜ ìˆë‚˜ìš”?"
- "í•™ì œê°„ í˜‘ë ¥ (ìƒë¬¼í•™ + í™”í•™ + ë°ì´í„° ì‚¬ì´ì–¸ìŠ¤)ì„ ì´‰ì§„í•˜ë ¤ë©´?"

**ë„¤íŠ¸ì›Œí‚¹ ê³¨ë“  íƒ€ì„**:
- Panel ëë‚˜ë©´ ì¦‰ì‹œ íƒ€ê²Ÿ ì—°ì‚¬ ì ‘ê·¼
- ì—¬ëŸ¬ ì—°ì‚¬ê°€ í•œ ê³³ì— ìˆìŒ (íš¨ìœ¨ì )
- ëª…í•¨ êµí™˜, ì €ë… ì‹ì‚¬ ì œì•ˆ

---

#### 18:30 | Closing Remark

**í™œìš©**:
- ë§ˆì§€ë§‰ ì¸ì‚¬
- ë¹ ì§„ ëª…í•¨ ìˆìœ¼ë©´ ìˆ˜ì§‘
- ë‹¤ìŒ ë‚  ì´ë©”ì¼ ì¤€ë¹„

---

## ğŸ¯ Networking Strategy

### ìµœìš°ì„  ì»¨íƒ (ë°”ì´ì˜¤ì¸í¬ ê´€ë ¨)

#### Tier 1A: ì§ì ‘ í˜‘ë ¥ ê°€ëŠ¥ (ë°”ì´ì˜¤ì¸í¬/ì»´í“¨íŒ…)

**1. Wonsik Lee (SKKU)**
- ì´ìœ : Tn-seq, genomics, ìœ ì „ì²´ ë°ì´í„° ë¶„ì„
- í˜‘ë ¥: RNA-seq + Tn-seq í†µí•©, ML ê¸°ë°˜ í‘œì  ì˜ˆì¸¡
- ì ‘ê·¼: ë°œí‘œ ì§í›„ + Break time + Panel í›„
- ì œì•ˆ: Lab visit (ìˆ˜ì›), ë°ì´í„° ê³µìœ , ê³µë™ ì—°êµ¬

**2. Hyunjung Lee (Institut Pasteur Korea)**
- ì´ìœ : ML/AI, high-content imaging, drug discovery
- í˜‘ë ¥: ML íŒŒì´í”„ë¼ì¸ ê³µìœ , compound screening
- ì ‘ê·¼: ë°œí‘œ ì§í›„ + Break time
- ì œì•ˆ: Internship/collaboration, HTS facility ì´ìš©

**3. Jung-Hyun Kim (Ajou Univ.)**
- ì´ìœ : scRNA-seq, organoid, cell-cell interaction
- í˜‘ë ¥: scRNA-seq ë¶„ì„, spatial transcriptomics
- ì ‘ê·¼: ë°œí‘œ ì§í›„ + Break time
- ì œì•ˆ: Computational analysis support

#### Tier 1B: ì¤‘ìš”í•œ ê³¼í•™ì  ë‚´ìš©

**4. Hongbaek Cho (SKKU)**
- ì´ìœ : AlphaFold2, structural bioinformatics
- í˜‘ë ¥: êµ¬ì¡° ì˜ˆì¸¡, docking simulation
- ì ‘ê·¼: ë°œí‘œ í›„

**5. Jinki Yeom (SNU)**
- ì´ìœ : SAR, structure-based design
- í˜‘ë ¥: Virtual screening, QSAR modeling
- ì ‘ê·¼: ë°œí‘œ í›„

**6. Yan Lee (SNU)**
- ì´ìœ : Peptide design, MD simulation
- í˜‘ë ¥: Computational peptide optimization
- ì ‘ê·¼: ë°œí‘œ í›„

#### Tier 2: ì‚°ì—…/ë°”ì´ì˜¤í…

**7. Jaehoon Yu (CAMP Therapeutics)**
- ì´ìœ : ë°”ì´ì˜¤í… ì°½ì—…, computational drug design
- ì ‘ê·¼: Panel í›„
- ë…¼ì˜: Career path, postdoc/scientist ì±„ìš©

**8. Hee-Jong Hwang (A&J Science)**
- ì´ìœ : ìì—°ë¬¼ discovery, ë°ì´í„°ë² ì´ìŠ¤
- ì ‘ê·¼: Panel í›„
- ë…¼ì˜: Partnership, screening

#### Tier 3: ê¸°íƒ€ ì—°ì‚¬

**9-13**: Patriq Fagerstedt, Sung Jae Shin, You-Hee Cho, Eun-Kyeong Jo
- ì ‘ê·¼: ì‹œê°„ ë˜ë©´
- ê´€ì‹¬ì‚¬ì— ë”°ë¼ ì„ íƒì 

---

## ğŸ“‹ Pre-Conference Preparation (D-7 to D-1)

### Week Before (10ì›” 23-29ì¼)

**D-7 (10ì›” 23ì¼, ëª©)**:
- [ ] ë°°ê²½ ìë£Œ 1ì°¨ ì½ê¸° (Session 1-4, ê° 1ì‹œê°„)
- [ ] ì—°ì‚¬ í”„ë¡œí•„ í™•ì¸ (Google Scholar, Lab website)

**D-6 (10ì›” 24ì¼, ê¸ˆ)**:
- [ ] ì£¼ìš” ë…¼ë¬¸ ë‹¤ìš´ë¡œë“œ (ì—°ì‚¬ë³„ ìµœê·¼ 1-2í¸)
- [ ] Abstract ì½ê¸°

**D-5 (10ì›” 25ì¼, í† )**:
- [ ] ë°°ê²½ ìë£Œ 2ì°¨ ì½ê¸° (í•µì‹¬ ë¶€ë¶„)
- [ ] ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ ì´ˆì•ˆ (ê° ë°œí‘œë³„ 2-3ê°œ)

**D-4 (10ì›” 26ì¼, ì¼)**:
- [ ] ëª…í•¨ ì¤€ë¹„ (30ì¥, ì˜ë¬¸)
- [ ] Elevator pitch ì—°ìŠµ (30ì´ˆ)
- [ ] ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ ìš°ì„ ìˆœìœ„ í™•ì •

**D-3 (10ì›” 27ì¼, ì›”)**:
- [ ] ë…¼ë¬¸ ì •ë… (Tier 1 ì—°ì‚¬ ë…¼ë¬¸)
- [ ] ë°”ì´ì˜¤ì¸í¬ ê´€ë ¨ ë‚´ìš© ì •ë¦¬

**D-2 (10ì›” 28ì¼, í™”)**:
- [ ] ì§ˆë¬¸ ìµœì¢… í™•ì • (3-5ê°œ)
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ ì¶©ì „ í™•ì¸
- [ ] Follow-up ì´ë©”ì¼ í…œí”Œë¦¿ ì¤€ë¹„

**D-1 (10ì›” 29ì¼, ìˆ˜)**:
- [ ] ë°°ê²½ ìë£Œ ë§ˆì§€ë§‰ ë¦¬ë·°
- [ ] êµí†µí¸ í™•ì¸ (ì„±ê· ê´€ëŒ€ ì˜ê³¼ëŒ€í•™ ìˆ˜ì›)
- [ ] ë¬¼ë¦¬ì  ì¤€ë¹„ (ëª…í•¨, ë³¼íœ, ë…¸íŠ¸, ì¶©ì „ê¸°)
- [ ] ì¼ì° ì·¨ì¹¨

---

## ğŸ“ Conference Day Checklist (10ì›” 30ì¼)

### Morning (í•™íšŒ ì „)

**11:00-11:30**:
- [ ] ì•„ì¹¨ ì‹ì‚¬ (ê°€ë³ê²Œ)
- [ ] ë°°ê²½ ìë£Œ í•µì‹¬ ë¦¬ë·° (30ë¶„)
- [ ] ì§ˆë¬¸ ì¹´ë“œ ì¤€ë¹„ (ì¢…ì´ì— ì ì–´ë‘ê¸°)

**11:30-12:00**:
- [ ] ì¶œë°œ (ì—¬ìœ  ìˆê²Œ)
- [ ] ë„ì°© (11:50 ëª©í‘œ)
- [ ] í™”ì¥ì‹¤, ì»¤í”¼
- [ ] ì•ìë¦¬ í™•ë³´

### During Conference (12:00-18:30)

**Sessionë³„ ì²´í¬ë¦¬ìŠ¤íŠ¸**:

**Session 1 (12:10-13:25)**:
- [ ] í•µì‹¬ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„ (Fagerstedt: OHAMR, Cho: Secretin, Yeom: ASM)
- [ ] ì§ˆë¬¸ 1ê°œ (Fagerstedt ë˜ëŠ” Cho)
- [ ] ë©”ëª¨ (ë°”ì´ì˜¤ì¸í¬ ì—°ê´€ ë‚´ìš©)

**Session 2 (13:40-14:55)**:
- [ ] Wonsik Lee ë°œí‘œ ì§‘ì¤‘!
- [ ] Tn-seq ë°©ë²•ë¡ , ë°ì´í„° ë¶„ì„ íŒŒì´í”„ë¼ì¸ ë©”ëª¨
- [ ] ì§ˆë¬¸ ì¤€ë¹„ (ë°”ì´ì˜¤ì¸í¬ ê´€ì )
- [ ] ìŠ¬ë¼ì´ë“œ ì‚¬ì§„ (Tn-seq ê²°ê³¼)

**Session 3 (15:10-16:25)**:
- [ ] Jung-Hyun Kim: scRNA-seq ë¶„ì„ ë°©ë²• ë©”ëª¨
- [ ] Hyunjung Lee: ML model details ë©”ëª¨
- [ ] ì§ˆë¬¸ ê° 1ê°œì”©
- [ ] Break timeì— ì¦‰ì‹œ ì ‘ê·¼

**Session 4 (16:40-17:55)**:
- [ ] Computational design ê´€ë ¨ ë‚´ìš© ë©”ëª¨
- [ ] ë°”ì´ì˜¤í… ê²½ë ¥ ì •ë³´ ìˆ˜ì§‘
- [ ] ì§ˆë¬¸ (computational approach)

**Panel Discussion (17:55-18:30)**:
- [ ] ì²­ì¤‘ ì§ˆë¬¸ ê¸°íšŒ ì‹œë„
- [ ] ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ ìµœì¢… í™•ì¸
- [ ] Panel ëë‚˜ë©´ ì¦‰ì‹œ ì´ë™

### Networking Moments

**Break 1 (13:25-13:40)**:
- [ ] Session 1 ë©”ëª¨ ì •ë¦¬ (5ë¶„)
- [ ] Session 2 ì¤€ë¹„ (ì§ˆë¬¸ ì¬í™•ì¸)
- [ ] ê°€ëŠ¥í•˜ë©´ Fagerstedt ì ‘ê·¼

**Break 2 (14:55-15:10)**:
- [ ] **Wonsik Lee ì¦‰ì‹œ ì ‘ê·¼** (ìµœìš°ì„ !)
- [ ] ëª…í•¨ êµí™˜, ì§§ì€ ëŒ€í™” (3ë¶„)
- [ ] Lab visit ì œì•ˆ

**Break 3 (16:25-16:40)**:
- [ ] Jung-Hyun Kim ì ‘ê·¼ (scRNA-seq)
- [ ] Hyunjung Lee ì ‘ê·¼ (ML)
- [ ] ëª…í•¨ êµí™˜, í˜‘ë ¥ ì œì•ˆ

**After Panel (18:30~)**:
- [ ] ë†“ì¹œ ì—°ì‚¬ ì ‘ê·¼ (Tier 2, 3)
- [ ] ì €ë… ì‹ì‚¬ ì œì•ˆ (ê°€ëŠ¥í•˜ë©´)
- [ ] ë§ˆì§€ë§‰ ëª…í•¨ ìˆ˜ì§‘

---

## ğŸ“§ Post-Conference Actions

### D+1 (10ì›” 31ì¼, ê¸ˆ)

**Morning**:
- [ ] ë©”ëª¨ ì •ë¦¬ (ë””ì§€í„¸í™”)
- [ ] ì‚¬ì§„ ë°±ì—… (ìŠ¬ë¼ì´ë“œ, ëª…í•¨)
- [ ] Follow-up ì´ë©”ì¼ ì‘ì„±

**Email Template** (Tier 1A ì—°ì‚¬ì—ê²Œ):

```
Subject: IAMRT 2025ì—ì„œ ëµ™ê²Œ ë˜ì–´ ì˜ê´‘ì´ì—ˆìŠµë‹ˆë‹¤ - [ê·€í•˜ì˜ ì´ë¦„]

Dear Professor/Dr. [ì´ë¦„],

10ì›” 30ì¼ IAMRT 2025ì—ì„œ "[ë°œí‘œ ì œëª©]" ë°œí‘œë¥¼
ë§¤ìš° í¥ë¯¸ë¡­ê²Œ ë“¤ì—ˆìŠµë‹ˆë‹¤.

íŠ¹íˆ [êµ¬ì²´ì  ë‚´ìš©, ì˜ˆ: Tn-seqì„ í†µí•œ í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì ë°œêµ´]ì´
ì €ì˜ ì—°êµ¬ ê´€ì‹¬ì‚¬ì¸ [ë°”ì´ì˜¤ì¸í¬/computational biology]ì™€
ê¹Šì´ ì—°ê²°ë  ìˆ˜ ìˆì„ ê²ƒ ê°™ì•„ ì—°ë½ë“œë¦½ë‹ˆë‹¤.

ì €ëŠ” [ì†Œì†]ì—ì„œ [ì—°êµ¬ ì£¼ì œ, ì˜ˆ: RNA-seq ë°ì´í„° ë¶„ì„ ë°
ë¨¸ì‹ ëŸ¬ë‹ì„ í™œìš©í•œ í•­ìƒì œ í‘œì  ì˜ˆì¸¡]ì„ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.

ì„ ìƒë‹˜ì˜ Tn-seq ë°ì´í„°ì™€ ì €í¬ì˜ [ë°©ë²•ë¡ ]ì„ í†µí•©í•˜ë©´,
[ëª©í‘œ, ì˜ˆ: S. aureusì˜ í™˜ê²½ë³„ gene expression ë³€í™”ë¥¼
ì˜ˆì¸¡í•˜ê³ , ì‹ ê·œ ì•½ë¬¼ í‘œì ì„ ë°œêµ´]í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.

ì²¨ë¶€í•œ 1-page summaryì— ì €í¬ ì—°êµ¬ë¥¼ ê°„ëµíˆ ì •ë¦¬í–ˆìŠµë‹ˆë‹¤.
ì‹œê°„ì´ ë˜ì‹ ë‹¤ë©´, Zoom ë¯¸íŒ… ë˜ëŠ” Lab visitì„ í†µí•´
í˜‘ë ¥ ê°€ëŠ¥ì„±ì„ ë…¼ì˜í•  ìˆ˜ ìˆì„ê¹Œìš”?

ê°ì‚¬í•©ë‹ˆë‹¤.

Best regards,
[ì´ë¦„]
[ì§ìœ„, ì˜ˆ: Postdoctoral Researcher]
[ì†Œì†]
[ì´ë©”ì¼]
[ì „í™”ë²ˆí˜¸]
[Google Scholar link]
```

**Afternoon**:
- [ ] ì´ë©”ì¼ ë°œì†¡ (Tier 1A: 3ëª…)
- [ ] LinkedIn ì—°ê²° ìš”ì²­
- [ ] í•™íšŒ ë…¸íŠ¸ ì •ë¦¬

### D+3 (11ì›” 2ì¼, ì¼)

- [ ] ì—°ì‚¬ ì‘ë‹µ í™•ì¸
- [ ] ì¶”ê°€ ìë£Œ ì½ê¸° (ë°œí‘œì—ì„œ ì–¸ê¸‰ëœ ë…¼ë¬¸)
- [ ] Lab visit ì¼ì • ì¡°ìœ¨

### D+7 (11ì›” 6ì¼, ëª©)

- [ ] Lab visit ì‹¤í–‰ (Wonsik Lee, SKKU)
- [ ] ë˜ëŠ” Zoom ë¯¸íŒ…
- [ ] Collaboration proposal ì´ˆì•ˆ

### D+14 (11ì›” 13ì¼, ëª©)

- [ ] Institut Pasteur Korea ë°©ë¬¸ (Hyunjung Lee)
- [ ] HTS facility íˆ¬ì–´
- [ ] Internship/collaboration ë…¼ì˜

### D+30 (11ì›” 29ì¼, ê¸ˆ)

- [ ] Collaboration project ì‹œì‘
- [ ] Grant ì‹ ì²­ ì¤€ë¹„ (NRF, KHIDI)
- [ ] ë…¼ë¬¸ ì•„ì´ë””ì–´ êµ¬ì²´í™”

---

## ğŸ’¡ Key Learnings & Action Items

### Immediate Takeaways (í•™íšŒ ì§í›„)

**ê³¼í•™ì **:
1. AMR ìœ„ê¸°ì˜ í˜„ì£¼ì†Œ (EU, í•œêµ­, ê¸€ë¡œë²Œ)
2. ê·¸ëŒìŒì„±ê·  ì™¸ë§‰ ëŒíŒŒ ì „ëµ 3ê°€ì§€ (CPP, Ribosome, pH-responsive)
3. Host-directed therapyì˜ ì„ìƒ ê°€ëŠ¥ì„±
4. Tn-seq, scRNA-seq, MLì˜ ì‹ ì•½ ë°œê²¬ ì‘ìš©

**ê¸°ìˆ ì **:
1. Tn-seq ë°ì´í„° ë¶„ì„ íŒŒì´í”„ë¼ì¸
2. scRNA-seq in organoid
3. ML for drug screening
4. AlphaFold2 in structural biology

**ë„¤íŠ¸ì›Œí‚¹**:
1. Wonsik Lee (Tn-seq collaboration)
2. Hyunjung Lee (ML/AI collaboration)
3. Jung-Hyun Kim (scRNA-seq collaboration)
4. ë°”ì´ì˜¤í… CEO 2ëª… (career insight)

### Short-term (1-3ê°œì›”)

**Research**:
- [ ] Tn-seq + RNA-seq integration project ì‹œì‘
- [ ] ML model for antibiotic target prediction ê°œë°œ
- [ ] Organoid scRNA-seq analysis pipeline êµ¬ì¶•

**Career**:
- [ ] Lab visit 3ê³³ (SKKU, Ajou, Pasteur Korea)
- [ ] Collaboration proposal 2ê±´
- [ ] Postdoc application (SKKU, Pasteur Korea)

**Learning**:
- [ ] Tn-seq ë¶„ì„ tutorial (online course)
- [ ] scRNA-seq advanced analysis (Seurat, Scanpy)
- [ ] ML for drug discovery (DeepChem, PyTorch)

### Long-term (6-12ê°œì›”)

**Publication**:
- [ ] Joint paper with Wonsik Lee (Tn-seq + transcriptomics)
- [ ] Method paper (ML for target prediction)
- [ ] Review paper (Bioinformatics in AMR)

**Grant**:
- [ ] NRF ë°•ì‚¬í›„ì—°êµ¬ì› ì§€ì› (with collaborator)
- [ ] KHIDI ê°ì—¼ë³‘ ì¹˜ë£Œì œ ê°œë°œ ê³¼ì œ
- [ ] International grant (EU OHAMR?)

**Career**:
- [ ] Postdoc position í™•ì • (SKKU or Pasteur Korea)
- [ ] ë˜ëŠ” ë°”ì´ì˜¤í… ì§„ì… (CAMP, A&J)
- [ ] Faculty application (ì¥ê¸°)

---

## ğŸ“Š Success Metrics

### Networking Success

**Goal**:
- ëª…í•¨ êµí™˜: 15ëª… ì´ìƒ
- ê¹Šì€ ëŒ€í™” (>5ë¶„): 5ëª… ì´ìƒ
- Follow-up ì‘ë‹µë¥ : 80% ì´ìƒ (Tier 1A)
- Lab visit í™•ì •: 2ê³³ ì´ìƒ

**Tracking**:
- Excel sheet (ì´ë¦„, ì†Œì†, ê´€ì‹¬ì‚¬, í›„ì† ì¡°ì¹˜)
- Reminder (ì¼ì •ë³„)

### Learning Success

**Immediate** (í•™íšŒ ë‹¹ì¼):
- [ ] ëª¨ë“  ë°œí‘œ ì°¸ì„ (13ê°œ)
- [ ] ì§ˆë¬¸ ìµœì†Œ 3ê°œ
- [ ] í•µì‹¬ ìŠ¬ë¼ì´ë“œ 30ì¥ ì´ìƒ ì‚¬ì§„

**Short-term** (1ì£¼ì¼):
- [ ] ë°œí‘œ ê´€ë ¨ ë…¼ë¬¸ 10í¸ ì½ê¸°
- [ ] í•™íšŒ ë…¸íŠ¸ ì •ë¦¬ (20 í˜ì´ì§€)
- [ ] ìƒˆë¡œìš´ ê¸°ìˆ /ë°©ë²• 3ê°€ì§€ ìŠµë“

**Long-term** (6ê°œì›”):
- [ ] Collaboration ì‹œì‘ (1-2ê±´)
- [ ] í•™íšŒì—ì„œ ë°°ìš´ ë‚´ìš© ë…¼ë¬¸ì— ì ìš©
- [ ] ë‹¤ìŒ í•™íšŒ ë°œí‘œ (MSK2025?)

---

## ğŸ“ Additional Resources

### Before Conference

**Reading List**:
1. EU OHAMR Strategic Plan (online)
2. Nature Commun 2025: Wonsik Lee (Tn-seq)
3. Cell Stem Cell 2024: Jung-Hyun Kim (Organoid)
4. PLoS Comput Biol 2024: ML + HTS

**Online Courses**:
1. Coursera: "Genomic Data Science"
2. YouTube: "Tn-seq tutorial" (Theo van Laar)
3. scRNA-seq analysis (Harvard Chan Bioinformatics)

### After Conference

**Communities**:
1. IAMRT mailing list (subscribe)
2. Korean Society for Microbiology
3. Institut Pasteur Korea seminar series
4. LinkedIn groups (AMR, Bioinformatics)

**Journals to Follow**:
1. Nature Microbiology
2. Cell Host & Microbe
3. Antimicrobial Agents and Chemotherapy
4. Bioinformatics

---

## ğŸ† Final Checklist

### D-1 (10ì›” 29ì¼)
- [ ] ë°°ê²½ ìë£Œ ë§ˆì§€ë§‰ ë¦¬ë·° ì™„ë£Œ
- [ ] ì§ˆë¬¸ 3-5ê°œ í™•ì •
- [ ] ëª…í•¨ 30ì¥ ì¤€ë¹„
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ ì¶©ì „
- [ ] êµí†µí¸ í™•ì¸
- [ ] Elevator pitch ì—°ìŠµ
- [ ] ì¼ì° ì·¨ì¹¨

### D-Day (10ì›” 30ì¼)
- [ ] 11:50 ë„ì°©
- [ ] ì•ìë¦¬ í™•ë³´
- [ ] ëª¨ë“  ë°œí‘œ ì°¸ì„
- [ ] Tier 1A ë„¤íŠ¸ì›Œí‚¹ ì™„ë£Œ
- [ ] ëª…í•¨ 15ëª… ì´ìƒ
- [ ] ì§ˆë¬¸ 3ê°œ ì´ìƒ
- [ ] ì¦ê¸°ê¸°! ğŸ˜Š

### D+1 (10ì›” 31ì¼)
- [ ] ë©”ëª¨ ì •ë¦¬
- [ ] Follow-up ì´ë©”ì¼ 3í†µ
- [ ] LinkedIn ì—°ê²°
- [ ] Lab visit ì¼ì • ì¡°ìœ¨

---

**Good luck and enjoy the conference!** ğŸ‰ğŸ”¬

**Remember**: This is not just a conference, it's the beginning of new collaborations, friendships, and career opportunities!

---

**ì‘ì„±**: 2025ë…„ 10ì›” 29ì¼
**ë²„ì „**: 2.0 (Comprehensive Plan)
**ì´ í˜ì´ì§€**: Conference Plan
**ì´ ë°°ê²½ ìë£Œ**: 6,174 ì¤„ (4ê°œ ì„¸ì…˜)

**ì´ ê³„íšì„ ë”°ë¼ê°€ë©´, IAMRT 2025ì—ì„œ ìµœëŒ€ì˜ ê°€ì¹˜ë¥¼ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤!**